StoryFunding
Kyverna secures $150M venture debt from Oxford Finance to fund development pipeline
Kyverna Therapeutics announced a $150M venture debt facility from Oxford Finance in October 2025, providing additional capital to advance its CAR-T pipeline without further dilution to shareholders. The company is preparing for regulatory submissions in 2026.